Onyda Xr is a drug owned by Tris Pharma Inc. It is protected by 2 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 28, 2041. Details of Onyda Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8062667 | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(4 years from now) | Active |
| US11918689 | Liquid clonidine extended release composition |
Jul, 2041
(16 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Onyda Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Onyda Xr's family patents as well as insights into ongoing legal events on those patents.
Onyda Xr's Family Patents
Try Our Curated Drug Screens
Generic Launch
Generic Release Date:
Onyda Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 28, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Onyda Xr Generics:
Clonidine Hydrochloride is the generic name for the brand Onyda Xr. 35 different companies have already filed for the generic of Onyda Xr, with Actavis Elizabeth having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Onyda Xr's generic
Onyda Xr Competitors
Understanding your competition is essential for market success. There are several other brand drugs using the same active ingredient (Clonidine Hydrochloride) as Onyda Xr. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Clonidine Hydrochloride, Onyda Xr's active ingredient. Check the complete list of approved generic manufacturers for Onyda Xr
About Onyda Xr
Onyda Xr is a drug owned by Tris Pharma Inc. Onyda Xr uses Clonidine Hydrochloride as an active ingredient. Onyda Xr was launched by Tris Pharma Inc in 2024.
Approval Date:
Onyda Xr was approved by FDA for market use on 24 May, 2024.
Active Ingredient:
Onyda Xr uses Clonidine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Clonidine Hydrochloride ingredient
Dosage:
Onyda Xr is available in suspension, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.1MG/ML | SUSPENSION, EXTENDED RELEASE | Prescription | ORAL |